PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2839259

Paraneoplastic limbic encephalopathy.

E G Camara·G J Chelune
View original source ↗Export metadata ↓

Abstract

Paraneoplastic limbic encephalopathy (PLE) is a remote, nonmetastatic complication of carcinoma. Neuropsychiatric symptoms consists of cognitive, affective, and behavioral changes that can predate the diagnosis of carcinoma by as much as 6 years. The most striking feature is the development of an amnestic syndrome without generalized intellectual decline. We report a case of PLE, including neuropsychological test results, and review the features of similar cases in the literature. The postulated causes and clinical implications of PLE are discussed.

Explore related subjects

Carcinoma, Small CellEncephalitisFemaleHumansLimbic SystemLung NeoplasmsMiddle AgedNeuropsychological TestsParaneoplastic SyndromesCase ReportsJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E G Camara, G J Chelune. 1987. Paraneoplastic limbic encephalopathy.. https://doi.org/10.1016/0889-1591(87)90038-9

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer.

The topoisomerase I inhibitor, topotecan, is approved for the treatment of recurrent small-cell lung cancer (SCLC) and ovarian cancer (OC). Patients with recurrent SCLC and OC typically experience multiple relapses and receive multiple rounds of chemotherapy. In these settings, disease stabilisation is considered a treatment benefit, and quality-of-life effects and cumulative toxicities of treatments should be considered. Many patients with recurrent cancer may be predisposed to treatment-related adverse events because of advanced age, renal impairment or extensive prior therapy. The standard regimen of topotecan, 1.5 mg/m(2) on days 1-5 of a 21-day cycle, has generally mild nonhaematological toxicity and a well-defined haematological toxicity profile characterised by reversible and noncumulative neutropenia. Alternative regimens may lower the incidence of haematological toxicities and maintain antitumour efficacy. Topotecan may provide physicians with a versatile therapeutic option for the treatment of patients with relapsed SCLC or OC.

Carcinoma, Small Cell↗